Todd Correll

Todd Correll has a diverse and extensive work experience in the pharmaceutical industry. Todd has held various roles in different companies, starting with their current position as the Vice President of Clinical Development Chronic Infections at Vir Biotechnology. Prior to that, Todd worked at Merck, where they served as the Executive Director and Program Development Team Lead for the Doravirine/Islatravir program. Todd also worked as a Senior Principle Scientist and Study Director at Merck. Before joining Merck, Todd worked at Bristol Myers Squibb, where they held roles such as Lung Fibrosis Clinical and Medical Affairs Lead, Liver and Lung Fibrosis Disease Strategy Lead, and Global Medical Director for HIV and Reyataz Development. Todd also worked at Abbott Laboratories as a Clinical Science Manager and at the University of North Carolina at Chapel Hill as a Clinical Pharmacy Specialist in Infectious Diseases and HIV.

Todd Correll attended the University of the Sciences in Philadelphia from 1996 to 2002, where they pursued a Doctor of Pharmacy (Pharm.D.) degree in the field of Pharmacy.